Vera Therapeutics (VERA) Competitors $23.74 +0.10 (+0.40%) Closing price 03:35 PM EasternExtended Trading$23.74 0.00 (0.00%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. NUVL, AXSM, AKRO, PCVX, ADMA, KRYS, ZLAB, RYTM, PTCT, and CYTKShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics Krystal Biotech Zai Lab Rhythm Pharmaceuticals PTC Therapeutics Cytokinetics Vera Therapeutics (NASDAQ:VERA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do institutionals & insiders hold more shares of VERA or NUVL? 99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by insiders. Comparatively, 10.2% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, VERA or NUVL? Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$152.15M-$3.00-7.92NuvalentN/AN/A-$260.76M-$4.39-18.31 Is VERA or NUVL more profitable? Nuvalent's return on equity of -31.35% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -40.59% -34.54% Nuvalent N/A -31.35%-29.27% Do analysts prefer VERA or NUVL? Vera Therapeutics presently has a consensus price target of $65.00, suggesting a potential upside of 173.74%. Nuvalent has a consensus price target of $119.60, suggesting a potential upside of 48.82%. Given Vera Therapeutics' higher probable upside, research analysts plainly believe Vera Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17 Which has more volatility and risk, VERA or NUVL? Vera Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Does the media prefer VERA or NUVL? In the previous week, Nuvalent had 19 more articles in the media than Vera Therapeutics. MarketBeat recorded 22 mentions for Nuvalent and 3 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.06 beat Nuvalent's score of 0.35 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 6 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVera Therapeutics beats Nuvalent on 7 of the 13 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.51B$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-7.9221.5627.4020.04Price / SalesN/A281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book2.627.518.085.67Net Income-$152.15M-$55.05M$3.16B$248.47M7 Day Performance1.95%3.16%2.12%2.90%1 Month Performance-23.18%5.92%4.43%5.75%1 Year Performance-31.94%5.82%35.62%21.36% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics3.5427 of 5 stars$23.75+0.4%$65.00+173.7%-32.3%$1.51BN/A-7.9240Positive NewsNUVLNuvalent3.7365 of 5 stars$75.98+1.3%$115.50+52.0%+10.3%$5.46BN/A-17.3140Analyst UpgradeInsider TradeAXSMAxsome Therapeutics4.6533 of 5 stars$101.65+1.0%$172.33+69.5%+31.6%$5.01B$385.69M-17.62380Analyst ForecastAnalyst RevisionAKROAkero Therapeutics3.7421 of 5 stars$54.03-0.3%$82.50+52.7%+131.8%$4.31BN/A-27.7130Insider TradePCVXVaxcyte1.7733 of 5 stars$33.25+1.2%$136.50+310.5%-56.3%$4.29BN/A-8.33160News CoveragePositive NewsADMAADMA Biologics4.2112 of 5 stars$17.87+0.7%$27.67+54.8%+59.1%$4.27B$426.45M21.02530KRYSKrystal Biotech4.5247 of 5 stars$137.92+4.1%$211.13+53.1%-20.4%$3.99B$290.52M33.15210Trending NewsAnalyst RevisionHigh Trading VolumeZLABZai Lab3.4124 of 5 stars$36.01+4.2%$47.37+31.5%+104.3%$3.97B$398.99M-14.461,869Analyst ForecastInsider TradeAnalyst RevisionGap UpRYTMRhythm Pharmaceuticals3.8053 of 5 stars$62.13+0.2%$76.62+23.3%+58.1%$3.95B$130.13M-22.11140PTCTPTC Therapeutics4.3213 of 5 stars$49.60-1.2%$65.00+31.0%+61.7%$3.93B$806.78M7.621,410Analyst RevisionCYTKCytokinetics4.3216 of 5 stars$32.64+0.6%$70.92+117.3%-37.3%$3.90B$18.47M-6.17250Positive News Related Companies and Tools Related Companies Nuvalent Competitors Axsome Therapeutics Competitors Akero Therapeutics Competitors Vaxcyte Competitors ADMA Biologics Competitors Krystal Biotech Competitors Zai Lab Competitors Rhythm Pharmaceuticals Competitors PTC Therapeutics Competitors Cytokinetics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VERA Stock Alerts